These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 17705877)

  • 1. An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data.
    Sugaya N; Ikeda K; Tashiro T; Takeda S; Otomo J; Ishida Y; Shiratori A; Toyoda A; Noguchi H; Takeda T; Kuhara S; Sakaki Y; Iwayanagi T
    BMC Pharmacol; 2007 Aug; 7():10. PubMed ID: 17705877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of mammalian two-hybrid technologies for high-throughput drug screening.
    Lievens S; Caligiuri M; Kley N; Tavernier J
    Methods; 2012 Dec; 58(4):335-42. PubMed ID: 22917772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovering reliable protein interactions from high-throughput experimental data using network topology.
    Chen J; Hsu W; Lee ML; Ng SK
    Artif Intell Med; 2005; 35(1-2):37-47. PubMed ID: 16055319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationalizing the chemical space of protein-protein interaction inhibitors.
    Sperandio O; Reynès CH; Camproux AC; Villoutreix BO
    Drug Discov Today; 2010 Mar; 15(5-6):220-9. PubMed ID: 19969101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the relationship between hub proteins and drug targets based on GO and intrinsic disorder.
    Fu Y; Guo Y; Wang Y; Luo J; Pu X; Li M; Zhang Z
    Comput Biol Chem; 2015 Jun; 56():41-8. PubMed ID: 25854804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Computational probing protein-protein interactions targeting small molecules.
    Wang YC; Chen SL; Deng NY; Wang Y
    Bioinformatics; 2016 Jan; 32(2):226-34. PubMed ID: 26415726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the druggability of protein-protein interactions by a supervised machine-learning method.
    Sugaya N; Ikeda K
    BMC Bioinformatics; 2009 Aug; 10():263. PubMed ID: 19703312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative real-time PCR as a sensitive protein-protein interaction quantification method and a partial solution for non-accessible autoactivator and false-negative molecule analysis in the yeast two-hybrid system.
    Maier RH; Maier CJ; Hintner H; Bauer JW; Onder K
    Methods; 2012 Dec; 58(4):376-84. PubMed ID: 22982175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico carborane docking to proteins and potential drug targets.
    Calvaresi M; Zerbetto F
    J Chem Inf Model; 2011 Aug; 51(8):1882-96. PubMed ID: 21774557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel in vitro protein fragment complementation assay applicable to high-throughput screening in a 1536-well format.
    Hashimoto J; Watanabe T; Seki T; Karasawa S; Izumikawa M; Seki T; Iemura S; Natsume T; Nomura N; Goshima N; Miyawaki A; Takagi M; Shin-Ya K
    J Biomol Screen; 2009 Sep; 14(8):970-9. PubMed ID: 19641222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of high-confidence protein-protein interactome in yeast.
    Karagoz K; Arga KY
    Comput Biol Chem; 2013 Aug; 45():1-8. PubMed ID: 23608186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database.
    Bourgeas R; Basse MJ; Morelli X; Roche P
    PLoS One; 2010 Mar; 5(3):e9598. PubMed ID: 20231898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prediction of network drug target based on improved model of bipartite graph valuation].
    Liu X; Lu P; Zuo X; Chen J; Yang H; Yang Y; Gao Y
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):125-9. PubMed ID: 22737836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utilizing shared interacting domain patterns and Gene Ontology information to improve protein-protein interaction prediction.
    Roslan R; Othman RM; Shah ZA; Kasim S; Asmuni H; Taliba J; Hassan R; Zakaria Z
    Comput Biol Med; 2010 Jun; 40(6):555-64. PubMed ID: 20417930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The analysis of the drug-targets based on the topological properties in the human protein-protein interaction network.
    Zhu M; Gao L; Li X; Liu Z; Xu C; Yan Y; Walker E; Jiang W; Su B; Chen X; Lin H
    J Drug Target; 2009 Aug; 17(7):524-32. PubMed ID: 19530902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The power of the yeast two-hybrid system in the identification of novel drug targets: building and modulating PPP1 interactomes.
    Silva JV; Freitas MJ; Felgueiras J; Fardilha M
    Expert Rev Proteomics; 2015 Apr; 12(2):147-58. PubMed ID: 25795147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FPPI: Fusarium graminearum protein-protein interaction database.
    Zhao XM; Zhang XW; Tang WH; Chen L
    J Proteome Res; 2009 Oct; 8(10):4714-21. PubMed ID: 19673500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-molecule protein-protein interaction inhibitors: therapeutic potential in light of molecular size, chemical space, and ligand binding efficiency considerations.
    Buchwald P
    IUBMB Life; 2010 Oct; 62(10):724-31. PubMed ID: 20979208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A discriminative approach for identifying domain-domain interactions from protein-protein interactions.
    Zhao XM; Chen L; Aihara K
    Proteins; 2010 Apr; 78(5):1243-53. PubMed ID: 20027642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.